You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

EGFR kinase domain mutations

Showing 1 - 25 of 6,255
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC, NSCLC, Carcinoma, Bronchogenic Trial in Worldwide (Furmonertinib)

Recruiting
  • Non-Small Cell Lung Cancer
  • +14 more
  • Glendale, California
  • +12 more
Feb 2, 2023

Non Small Cell Lung Cancer Trial in Mexico City (Metformin Hydrochloride, Placebo)

Recruiting
  • Non Small Cell Lung Cancer
  • Metformin Hydrochloride
  • Placebo
  • Mexico City, Mexico
    Instituto Nacional de Cancerologia
Jul 21, 2022

Lung Cancer, Non-squamous, Non-small Cell Trial (zongertinib, pembrolizumab, cisplatin)

Not yet recruiting
  • Lung Cancer, Non-squamous, Non-small Cell
  • (no location specified)
Nov 22, 2023

Lung Tumor Malignant, NSCLC, Respiratory Tract Tumors Trial in United States (BLU-451)

Recruiting
  • Lung Neoplasm Malignant
  • +18 more
  • Fairfax, Virginia
    New Experimental Therapeutics of Virginia (NEXT Oncology)
Mar 29, 2022

Pre-existing Kinase Domain Mutations in Ph-positive Leukemias

Recruiting
  • Leukemia
    • Vienna, Austria
      Medical Universitiy of Vienna
    Mar 23, 2021

    Resistance-associated Mutations in Metastatic Lung Cancer

    Recruiting
    • Lung Cancer
    • Liquid biopsy
    • Monza, MB, Italy
      Fondazione IRCCS San Gerardo dei Tintori
    Oct 10, 2023

    NSCLC Trial in China (BBP-398, osimertinib)

    Recruiting
    • NSCLC
    • Beijing, Beijing, China
    • +4 more
    Sep 4, 2023

    NSCLC, NSCLC, Carcinoma, Bronchogenic Trial in United States (furmonertinib 240 mg, furmonertinib 160 mg, platinum-based chemo)

    Recruiting
    • Non-Small Cell Lung Cancer
    • +13 more
    • furmonertinib 240 mg
    • +2 more
    • Yuma, Arizona
    • +37 more
    Dec 14, 2022

    NSCLC Stage II, NSCLC, Stage IIIA Trial in Goyang-si (Erlotinib)

    Active, not recruiting
    • NSCLC Stage II
    • NSCLC, Stage IIIA
    • Goyang-si, Gyeonggi-do, Korea, Republic of
      National Cancer Center
    Apr 4, 2022

    Recurrent Non-Small Cell Lung Carcinoma, Stage IV NSCLC Trial in United States (Laboratory Biomarker Analysis, Paclitaxel

    Completed
    Has Results
    • Recurrent Non-Small Cell Lung Carcinoma
    • Stage IV Non-Small Cell Lung Cancer
    • Laboratory Biomarker Analysis
    • Paclitaxel Albumin-Stabilized Nanoparticle Formulation
    • Anchorage, Alaska
    • +11 more
    Jun 26, 2021

    Solid Tumor Trial in Worldwide (BDTX-189)

    Terminated
    • Solid Tumor
    • Scottsdale, Arizona
    • +37 more
    Oct 13, 2022

    NSCLC Trial in Italy (Osimertinib, Dacomitinib)

    Recruiting
    • NSCLC
    • Arezzo, AR, Italy
    • +19 more
    May 4, 2021

    NSCLC (NSCLC) Trial (MK-2870, Docetaxel, Pemetrexed)

    Not yet recruiting
    • Non-small Cell Lung Cancer (NSCLC)
    • MK-2870
    • +2 more
    • (no location specified)
    Oct 3, 2023

    NSCLC Trial (Furmonertinib)

    Not yet recruiting
    • Non-Small Cell Lung Cancer
    • (no location specified)
    Aug 10, 2023

    OSIREAL - Osimertinib RWE on EGFRm NSCLC in Spain

    Recruiting
    • Non-small Cell Lung Cancer
      • Santiago de Compostela, Galicia, Spain
        Luis Ángel Leon Mateos
      Oct 3, 2023

      NSCLC Trial (Sutetinib Maleate Capsule)

      Not yet recruiting
      • Non-small Cell Lung Cancer
      • Sutetinib Maleate Capsule
      • (no location specified)
      Aug 18, 2023

      EGFR Activating Mutation, Recurrent Non-Small Cell Lung Carcinoma, Stage IV NSCLC Trial in Winston-Salem (drug, biological,

      Terminated
      • EGFR Activating Mutation
      • +2 more
      • Winston-Salem, North Carolina
        Comprehensive Cancer Center of Wake Forest University
      Jan 28, 2021

      EGF-R Positive NSCLC, Non Small Cell Lung Cancer, EGFR Exon 19 Deletion Trial in Bogotá (Stereotactic Body Radiation Therapy

      Not yet recruiting
      • EGF-R Positive Non-Small Cell Lung Cancer
      • +4 more
      • Stereotactic Body Radiation Therapy SBRT
      • Bogotá, Colombia
        CTIC - Centro de Tratamiento e Investigación Sobre Cáncer Luis C
      Aug 16, 2023

      NSCLC (NSCLC) Trial in Worldwide (U3-1402 (FL-DP), U3-1402 (CTM-1 Lyo-DP), U3-1402 (CTM-3 Lyo-DP))

      Recruiting
      • Non-Small Cell Lung Cancer (NSCLC)
      • U3-1402 (FL-DP)
      • +2 more
      • Duarte, California
      • +21 more
      Jul 5, 2022

      NSCLC Trial in Singapore (Afatinib 40 MG)

      Not yet recruiting
      • NSCLC
      • Afatinib 40 MG
      • Singapore, Singapore
        National University Hospital
      Sep 25, 2023

      NSCLC Trial in Worldwide (Afatinib)

      Completed
      Has Results
      • NSCLC
      • Köln, Germany
      • +4 more
      Aug 23, 2022

      Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7

      Active, not recruiting
      • Metastatic Lung Non-Small Cell Carcinoma
      • +2 more
      • Duarte, California
      • +14 more
      Jan 27, 2023

      Non Small Cell Lung Cancer Trial in Durham, Columbus, Pittsburgh (osimertinib)

      Active, not recruiting
      • Non Small Cell Lung Cancer
      • Durham, North Carolina
      • +2 more
      Jun 30, 2022

      A Retrospective Pharmacogenomics Research of EGFR-TKIs,Gefitinib

      Recruiting
      • Non-small Cell Lung Cancer (NSCLC)
      • +4 more
        • Guangzhou, Guangdong, China
          Cancer Center, Sun Yat-sen University
        Oct 25, 2022

        NSCLC, Epidermal Growth Factor Receptor, Leptomeningeal Metastasis Trial (Pemetrexed)

        Not yet recruiting
        • Carcinoma, Non-Small-Cell Lung
        • +2 more
        • (no location specified)
        Mar 27, 2023